Postpericardiotomy syndrome incidence, diagnostic and treatment strategies: experience AT two collaborative centers

Krešimir Gabaldo, Željko Sutlić, Domagoj Mišković, Marijana Knežević Praveček, Đeiti Prvulović, Božo Vujeva, Katica Cvitkušić Lukenda, Irzal Hadžibegović, Krešimir Gabaldo, Željko Sutlić, Domagoj Mišković, Marijana Knežević Praveček, Đeiti Prvulović, Božo Vujeva, Katica Cvitkušić Lukenda, Irzal Hadžibegović

Abstract

Postpericardiotomy syndrome (PPS) is worsening or new formation of pericardial and/or pleural effusion mostly 1 to 6 weeks after cardiac surgery, as a result of autoimmune inflammatory reaction within pleural and pericardial space. Its incidence varies among different studies and registries (2% to 30%), as well as according to the type of cardiac surgery performed. We conducted this retrospective analysis of PPS incidence and diagnostic and treatment strategies in patients referred for cardiac surgery for revascularization, valvular and/or aortic surgery. We retrospectively analyzed 461 patients referred for an urgent or elective cardiac surgery procedure between 2009 and 2015. PPS diagnosis was established using well defined clinical criteria. Demographic and clinical characteristics were used in regression subanalysis among patients having undergone surgery of aortic valve and/or ascending aorta. Within 6 weeks after cardiac surgery, 47 (10.2%) patients had PPS. The median time from the procedure to PPS diagnosis was 14 days. The incidence of PPS was 26% after aortic valve and/or aorta surgery, and 7.9% and 8.3% after coronary bypass and mitral valve surgery, respectively. Among patients subjected to aortic valve and/or aortic surgery, regression analysis showed significant association of fever, C-reactive protein (CRP) elevation between 5 and 100 mg/L, urgent procedure and postoperative antibiotic use with PPS diagnosis, whereas younger age showed near-significant association. All patients had complete resolution of PPS, mostly after corticosteroid therapy, with only 2 cases of recurrent PPS that successfully resolved after colchicine therapy. Pleural drainage was indicated in 15 (32%) patients, whereas only one patient required pericardial drainage. In conclusion, PPS incidence in our retrospective analysis was similar to previous reports. Patients having undergone aortic valve and/or aortic surgery were most likely to develop PPS. The most relevant clinical criteria for diagnosis in these patients were fever, CRP elevation between 5 and 100 mg/L, and pericardial and/or pleural effusion formation or worsening 2 weeks after cardiac surgery.

Keywords: Cardiac surgical procedures; Pericardial effusion; Pleural effusion; Postoperative complications; Postpericardiotomy syndrome.

Figures

Fig. 1
Fig. 1
Significantly higher proportion of postpericardiotomy syndrome among patients referred for surgery of the aortic valve and/or thoracic aorta compared to coronary artery bypass graft and mitral valve surgery.

References

    1. Miller RH, Horneffer PJ, Gardner TJ, Rykiel MF, Pearson TA. The epidemiology of the postpericardiotomy syndrome: a common complication of cardiac surgery. Am Heart J. 1988;116:1323–9. 10.1016/0002-8703(88)90457-7
    1. Bartels C, Honig R, Burger G, Diehl V, de Vivie R. The significance of anticardiolipin antibodies and anti-heart muscle antibodies for the diagnosis of postpericardiotomy syndrome. Eur Heart J. 1994;15:1494–9. 10.1093/oxfordjournals.eurheartj.a060420
    1. Imazio M, Trinchero R, Brucato A, Ferrazzi P, Rovere ME, Gandino A, et al. COPPS Investigators. Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31:2749–54. 10.1093/eurheartj/ehq319
    1. Imazio M, Hoit BD. Post-cardiac injury syndromes: an emerging cause of pericardial diseases. Int J Cardiol. 2013;168:648–52. 10.1016/j.ijcard.2012.09.052
    1. Light RW. The Light criteria: the beginning and why they are useful 40 years later. Clin Chest Med. 2013;34:21–6. 10.1016/j.ccm.2012.11.006
    1. Lehto J, Gunn J, Karjalainen P, Airaksinen J, Kiviniemi T. Incidence and risk factors of postpericardiotomy syndrome requiring medical attention: The Finland Postpericardiotomy Syndrome study. J Thorac Cardiovasc Surg. 2015;149:1324–29. 10.1016/j.jtcvs.2015.01.031
    1. Horneffer PJ, Miller RH, Pearson TA, Rykiel MF, Reitz BA, Gardner TJ. The effective treatment of postpericardiotomy syndrome after cardiac operations: a randomized placebo controlled trial. J Thorac Cardiovasc Surg. 1990;100(2):292–6.
    1. Imazio M, Brucato A, Rovere ME, Gandino A, Cemin R, Ferrua S, et al. Contemporary features, risk factors, and prognosis of the postpericardiotomy syndrome. Am J Cardiol. 2011;108:1183–7. 10.1016/j.amjcard.2011.06.025
    1. Bunge JJ, van Osch D, Dieleman JM, Jacob KA, Kluin J, van Dijk D, et al. Dexamethasone for Cardiac Surgery (DECS) Study Group Dexamethasone for the prevention of postpericardiotomy syndrome: a DExamethasone for Cardiac Surgery substudy. Am Heart J. 2014;168:126–31.e1. 10.1016/j.ahj.2014.03.017
    1. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al. COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312:1016–23. 10.1001/jama.2014.11026
    1. Makarović S, Makarović Z, Bilić-Ćurčić I, Milas-Ahić J, Mihaljević I, Franceschi M, et al. Serum osteoprotegerin in patients with calcified aortic valve stenosis in relation to heart failure. Acta Clin Croat. 2017;56:733–41. 10.20471/acc.2017.56.04.22

Source: PubMed

3
Abonnere